New study aims to uncover hidden threat of enterovirus in newborns

NCT ID NCT07356583

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking enterovirus infections in newborns across Italy, with a special focus on a dangerous strain called Echovirus 11. Researchers will analyze samples from 1,600 babies in intensive care to understand how common these infections are, what makes some cases severe, and how the virus spreads. The goal is to build a surveillance system that could help detect and respond to outbreaks faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better surveillance and early detection of dangerous enterovirus strains in newborns, potentially reducing severe illness and deaths.
What could go wrong: This is an observational study, not a treatment trial. It will not directly test any therapy, and results may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system disorder enterovirus infectious disease infectious disease with sepsis Sepsis syndromic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL SYNDROME ENTEROVIRUS GASTROINTESTINAL RESPIRATORY COMPLICATIONS SEPSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fondazione IRCCS Policlinico San Matteo
RECRUITING

Pavia, Lombardy, 27100, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.